Screener
Corcept Therapeutics CORT Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCash.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash, cash equivalents and restricted cash, at beginning of period | 121,745 | 128,665 |
| Cash, cash equivalents and restricted cash, at end of period | $112,289 | $103,745 |
| Supplemental disclosure: | ||
| Exercise cost of shares repurchased for net settlement of cashless option exercises | $14,331 | $12,056 |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $111,039 | $102,745 |
| Restricted cash included in Other assets | 1,250 | 1,000 |
| Cash, cash equivalents and restricted cash, at end of period | $112,289 | $103,745 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's restricted cash?
- Corcept Therapeutics (CORT) reported restricted cash of $1.25M in Q2 2026.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Corcept Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude